<DOC>
	<DOC>NCT01986127</DOC>
	<brief_summary>We study if the administration of intralesional Adalimumab (directly injected in the stricture) associated to endoscopic dilatation has a higher success rate at week 8 compared with placebo in patients with Crohn's disease who had confirmed intestinal stenosis (3 stenosis as maximum)</brief_summary>
	<brief_title>Adalimumab Intralesional in Intestinal Strictures of Crohn's Disease Patients</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Constriction, Pathologic</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Patients of both sexes older than 18 years Patient diagnosed of CROHNÂ´s disease Patient with intestinal stenosis length equal or less than 5cm previously confirmed with bowel magnetic resonance imaging (3 stenosis as maximum) Stenosis no permeable for endoscopy(12mm in case of accessible stenosis with conventional colonoscopy and 10mm in case of accessible stenosis with balloon enteroscopy) Dilated stenosis according to endoscopist criteria (pass or no the endoscopy) Patient capable of participate in the examinations required by the study Patient after being informed, give his/her informed consent in writing Patients with large intestinal stenosis (more than 6cm) and multiples Patients with previous or actual treatment with antitumor necrosis factor (antiTNF) drugs Patients with positive serology to hepatitis B virus(HBV),hepatitis C virus (HCV), or HIV Patients with positive screening to Tuberculosis(positive PPD) Established contraindication to antiTNF drugs Existence of fistulous tracts associated with intestinal stenosis Neoplastic process associated with stenosis or in another location Pregnancy or breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Crohn disease</keyword>
</DOC>